Anti-tat Hutat2: Fc mediated protection against tat-induced neurotoxicity and HIV-1 replication in human monocyte-derived macrophages

Journal of Neuroinflammation

Volumn 11, Issue 1, 2014, Pages

  Kang, Wen ^a,b   Marasco, Wayne A ^c   Tong, Hsin I ^b   Byron, Mary Margaret ^b   Wu, Chengxiang ^b   Shi, Yingli ^b   Sun, Si ^b   Sun, Yongtao ^a   Lu, Yuanan ^b  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF HAWAII   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Anti Tat antibody; HIV 1; HIV associated neurocognitive disorders; Human monocyte derived macrophages; Lentivirus; Neuroprotection

Indexed keywords

HUTAT2 FC FRAGMENT FUSION PROTEIN; HYBRID PROTEIN; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE 1; INTERLEUKIN 8; LENTIVIRUS VECTOR; PROTEIN ANTIBODY; STAT1 PROTEIN; TRANSACTIVATOR PROTEIN; TRANSACTIVATOR PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIBODY PRODUCTION; ARTICLE; BLOOD BRAIN BARRIER; CELL STRUCTURE; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG PENETRATION; DRUG SAFETY; GENE EXPRESSION; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; IN VITRO STUDY; MACROPHAGE; MONOCYTE DERIVED MACROPHAGE; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; STABLE EXPRESSION; SUPERNATANT; UPREGULATION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS NEUTRALIZATION; VIRUS REPLICATION; ANIMAL; BAGG ALBINO MOUSE; CELL CULTURE; CELL LINE; DRUG EFFECTS; HEK293 CELL LINE; MONOCYTE; PHYSIOLOGY; U-937 CELL LINE; VIROLOGY;

ANIMALS; CELL LINE; CELLS, CULTURED; HEK293 CELLS; HIV-1; HUMANS; MACROPHAGES; MICE; MICE, INBRED BALB C; MONOCYTES; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; U937 CELLS; VIRUS REPLICATION;

EID: 84988660825     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/s12974-014-0195-2     Document Type: Article

References (108)

1. Clifford DB, Ances BM: HIV-associated neurocognitive disorder. Lancet Infect Dis 2013, 13:976-986.
2. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, Clifford DB, Cinque P, Epstein LG, Goodkin K, Gisslen M, Grant I, Heaton RK, Joseph J, Marder K, Marra CM, McArthur JC, Nunn M, Price RW, Pulliam L, Robertson KR, Sacktor N, Valcour V, Wojna VE: Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007, 69:1789-1799.
3. Heaton RK, Clifford DB, Franklin DR Jr, Woods SP, Ake C, Vaida F, Ellis RJ, Letendre SL, Marcotte TD, Atkinson JH, Rivera-Mindt M, Vigil OR, Taylor MJ, Collier AC, Marra CM, Gelman BB, McArthur JC, Morgello S, Simpson DM, McCutchan JA, Abramson I, Gamst A, Fennema-Notestine C, Jernigan TL, Wong J, Grant I, CHARTER Group: HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 2010, 75:2087-2096.
4. Kanmogne GD, Kuate CT, Cysique LA, Fonsah JY, Eta S, Doh R, Njamnshi DM, Nchindap E, Franklin DR Jr, Ellis RJ, McCutchan JA, Binam F, Mbanya D, Heaton RK, Njamnshi AK: HIV-associated neurocognitive disorders in sub-Saharan Africa: a pilot study in Cameroon. BMC Neurol 2010, 10:60.
5. Simioni S, Cavassini M, Annoni JM, Rimbault Abraham A, Bourquin I, Schiffer V, Calmy A, Chave JP, Giacobini E, Hirschel B, Du Pasquier RA: Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS 2010, 24:1243-1250.
6. Thomas SA: Anti-HIV drug distribution to the central nervous system. Curr Pharm Des 2004, 10:1313-1324.
7. Letendre S, Marquie-Beck J, Capparelli E, Best B, Clifford D, Collier AC, Gelman BB, McArthur JC, McCutchan JA, Morgello S, Simpson D, Grant I, Ellis RJ, CHARTER Group: Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008, 65:65-70.
8. Alfahad TB, Nath A: Update on HIV-associated neurocognitive disorders. Curr Neurol Neurosci Rep 2013, 13:387.
9. Rao VR, Ruiz AP, Prasad VR: Viral and cellular factors underlying neuropathogenesis in HIV associated neurocognitive disorders (HAND). AIDS Res Ther 2014, 11:13.
10. Ellis RJ, Letendre S, Vaida F, Haubrich R, Heaton RK, Sacktor N, Clifford DB, Best BM, May S, Umlauf A, Cherner M, Sanders C, Ballard C, Simpson DM, Jay C, McCutchan JA: Randomized trial of central nervous systemtargeted antiretrovirals for HIV-associated neurocognitive disorder. Clin Infect Dis 2014, 58:1015-1022.
11. Caniglia EC, Cain LE, Justice A, Tate J, Logan R, Sabin C, Winston A, van Sighem A, Miro JM, Podzamczer D, Olson A, Arribas JR, Moreno S, Meyer L, del Romero J, Dabis F, Bucher HC, Wandeler G, Vourli G, Skoutelis A, Lanoy E, Gasnault J, Costagliola D, Hernán MA, HIV-CAUSAL Collaboration: Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions. Neurology 2014, 83:134-141.
12. Di Nunzio F, Felix T, Arhel NJ, Nisole S, Charneau P, Beignon AS: HIVderived vectors for therapy and vaccination against HIV. Vaccine 2012, 30:2499-2509.
13. Liang X, Casimiro DR, Schleif WA, Wang F, Davies ME, Zhang ZQ, Fu TM, Finnefrock AC, Handt L, Citron MP, Heidecker G, Tang A, Chen M, Wilson KA, Gabryelski L, McElhaugh M, Carella A, Moyer C, Huang L, Vitelli S, Patel D, Lin J, Emini EA, Shiver JW: Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys. J Virol 2005, 79:12321-12331.
14. Someya K, Xin KQ, Ami Y, Izumi Y, Mizuguchi H, Ohta S, Yamamoto N, Honda M, Okuda K: Chimeric adenovirus type 5/35 vector encoding SIV gag and HIV env genes affords protective immunity against the simian/human immunodeficiency virus in monkeys. Virology 2007, 367:390-397.
15. Peters BS: The basis for HIV immunotherapeutic vaccines. Vaccine 2001, 20:688-705.
16. Ahluwalia JK, Khan SZ, Soni K, Rawat P, Gupta A, Hariharan M, Scaria V, Lalwani M, Pillai B, Mitra D, Brahmachari SK: Human cellular microRNA hsamiR-29a interferes with viral nef protein expression and HIV-1 replication. Retrovirology 2008, 5:117.
17. Nielsen MH, Pedersen FS, Kjems J: Molecular strategies to inhibit HIV-1 replication. Retrovirology 2005, 2:10.
18. Novina CD, Murray MF, Dykxhoorn DM, Beresford PJ, Riess J, Lee SK, Collman RG, Lieberman J, Shankar P, Sharp PA: siRNA-directed inhibition of HIV-1 infection. Nat Med 2002, 8:681-686.
19. Wu C, Nerurkar VR, Lu Y: New insights into inhibition of human immunodeficiency virus type 1 replication through mutant tRNALys3. Retrovirology 2013, 10:112.
20. Abdel-Motal UM, Sarkis PT, Han T, Pudney J, Anderson DJ, Zhu Q, Marasco WA: Anti-gp120 minibody gene transfer to female genital epithelial cells protects against HIV-1 virus challenge in vitro. PLoS One 2011, 6:e26473.
21. Bouchet J, Basmaciogullari SE, Chrobak P, Stolp B, Bouchard N, Fackler OT, Chames P, Jolicoeur P, Benichou S, Baty D: Inhibition of the Nef regulatory protein of HIV-1 by a single-domain antibody. Blood 2011, 117:3559-3568.
22. Braun SE, Taube R, Zhu Q, Wong FE, Murakami A, Kamau E, Dwyer M, Qiu G, Daigle J, Carville A, Johnson RP, Marasco WA: In vivo selection of CD4(+) T cells transduced with a gamma-retroviral vector expressing a singlechain intrabody targeting HIV-1 tat. Hum Gene Ther 2012, 23:917-931.
23. Theisen DM, Pongratz C, Wiegmann K, Rivero F, Krut O, Kronke M: Targeting of HIV-1 Tat traffic and function by transduction-competent single chain antibodies. Vaccine 2006, 24:3127-3136.
24. Cao S, Wu C, Yang Y, Sniderhan LF, Maggirwar SB, Dewhurst S, Lu Y: Lentiviral vector-mediated stable expression of sTNFR-Fc in human macrophage and neuronal cells as a potential therapy for neuroAIDS. J Neuroinflammation 2011, 8:48.
25. Tong J, Buch S, Yao H, Wu C, Tong HI, Wang Y, Lu Y: Monocytes-derived macrophages mediated stable expression of human brain-derived neurotrophic factor, a novel therapeutic strategy for neuroAIDS. PLoS One 2014, 9:e82030.
26. Ensoli B, Buonaguro L, Barillari G, Fiorelli V, Gendelman R, Morgan RA, Wingfield P, Gallo RC: Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. J Virol 1993, 67:277-287.
27. Banks WA, Robinson SM, Nath A: Permeability of the blood-brain barrier to HIV-1 Tat. Exp Neurol 2005, 193:218-227.
28. Buscemi L, Ramonet D, Geiger JD: Human immunodeficiency virus type-1 protein Tat induces tumor necrosis factor-alpha-mediated neurotoxicity. Neurobiol Dis 2007, 26:661-670.
29. Agrawal L, Louboutin JP, Reyes BA, Van Bockstaele EJ, Strayer DS: HIV-1 Tat neurotoxicity: a model of acute and chronic exposure, and neuroprotection by gene delivery of antioxidant enzymes. Neurobiol Dis 2012, 45:657-670.
30. Price TO, Ercal N, Nakaoke R, Banks WA: HIV-1 viral proteins gp120 and Tat induce oxidative stress in brain endothelial cells. Brain Res 2005, 1045:57-63.
31. Magnuson DS, Knudsen BE, Geiger JD, Brownstone RM, Nath A: Human immunodeficiency virus type 1 tat activates non-N-methyl-D-aspartate excitatory amino acid receptors and causes neurotoxicity. Ann Neurol 1995, 37:373-380.
32. Chandra T, Maier W, Konig HG, Hirzel K, Kogel D, Schuler T, Chandra A, Demirhan I, Laube B: Molecular interactions of the type 1 human immunodeficiency virus transregulatory protein Tat with N-methyl-daspartate receptor subunits. Neuroscience 2005, 134:145-153.
33. Self RL, Mulholland PJ, Nath A, Harris BR, Prendergast MA: The human immunodeficiency virus type-1 transcription factor Tat produces elevations in intracellular Ca2+ that require function of an N-methyl-Daspartate receptor polyamine-sensitive site. Brain Res 2004, 995:39-45.
34. Kim TA, Avraham HK, Koh YH, Jiang S, Park IW, Avraham S: HIV-1 Tatmediated apoptosis in human brain microvascular endothelial cells. J Immunol 2003, 170:2629-2637.
35. Campbell GR, Watkins JD, Singh KK, Loret EP, Spector SA: Human immunodeficiency virus type 1 subtype C Tat fails to induce intracellular calcium flux and induces reduced tumor necrosis factor production from monocytes. J Virol 2007, 81:5919-5928.
36. Yang Y, Wu J, Lu Y: Mechanism of HIV-1-TAT induction of interleukin-1beta from human monocytes: Involvement of the phospholipase C/protein kinase C signaling cascade. J Med Virol 2010, 82:735-746.
37. Mhashilkar AM, LaVecchio J, Eberhardt B, Porter-Brooks J, Boisot S, Dove JH, Pumphrey C, Li X, Weissmahr RN, Ring DB, Ramstedt U, Marasco WA: Inhibition of human immunodeficiency virus type 1 replication in vitro in acutely and persistently infected human CD4+ mononuclear cells expressing murine and humanized anti-human immunodeficiency virus type 1 Tat singlechain variable fragment intrabodies. Hum Gene Ther 1999, 10:1453-1467.
38. Poznansky MC, La Vecchio J, Silva-Arietta S, Porter-Brooks J, Brody K, Olszak IT, Adams GB, Ramstedt U, Marasco WA, Scadden DT: Inhibition of human immunodeficiency virus replication and growth advantage of CD4+ T cells and monocytes derived from CD34+ cells transduced with an intracellular antibody directed against human immunodeficiency virus type 1 Tat. Hum Gene Ther 1999, 10:2505-2514.
39. Marasco WA, LaVecchio J, Winkler A: Human anti-HIV-1 tat sFv intrabodies for gene therapy of advanced HIV-1-infection and AIDS. J Immunol Methods 1999, 231:223-238.
40. Zeng L, Yang S, Wu C, Ye L, Lu Y: Effective transduction of primary mouse blood-and bone marrow-derived monocytes/macrophages by HIVbased defective lentiviral vectors. J Virol Methods 2006, 134:66-73.
41. Wu C, Lu Y: Inclusion of high molecular weight dextran in calcium phosphate-mediated transfection significantly improves gene transfer efficiency. Cell Mol Biol (Noisy-le-grand) 2007, 53:67-74.
42. Wu C, Lu Y: High-titre retroviral vector system for efficient gene delivery into human and mouse cells of haematopoietic and lymphocytic lineages. J Gen Virol 2010, 91:1909-1918.
43. Beaudoin GM 3rd, Lee SH, Singh D, Yuan Y, Ng YG, Reichardt LF, Arikkath J: Culturing pyramidal neurons from the early postnatal mouse hippocampus and cortex. Nat Protoc 2012, 7:1741-1754.
44. Mizuguchi H, Xu Z, Ishii-Watabe A, Uchida E, Hayakawa T: IRES-dependent second gene expression is significantly lower than cap-dependent first gene expression in a bicistronic vector. Mol Ther 2000, 1:376-382.
45. Mondal D, Williams CA, Ali M, Eilers M, Agrawal KC: The HIV-1 Tat protein selectively enhances CXCR4 and inhibits CCR5 expression in megakaryocytic K562 cells. Exp Biol Med (Maywood) 2005, 230:631-644.
46. Agrawal L, Louboutin JP, Strayer DS: Preventing HIV-1 Tat-induced neuronal apoptosis using antioxidant enzymes: mechanistic and therapeutic implications. Virology 2007, 363:462-472.
47. Minagar A, Shapshak P, Fujimura R, Ownby R, Heyes M, Eisdorfer C: The role of macrophage/microglia and astrocytes in the pathogenesis of three neurologic disorders: HIV-associated dementia, Alzheimer disease, and multiple sclerosis. J Neurol Sci 2002, 202:13-23.
48. Mind Exchange Working G: Assessment, diagnosis, and treatment of HIVassociated neurocognitive disorder: a consensus report of the mind exchange program. Clin Infect Dis 2013, 56:1004-1017.
49. Apolloni A, Hooker CW, Mak J, Harrich D: Human immunodeficiency virus type 1 protease regulation of tat activity is essential for efficient reverse transcription and replication. J Virol 2003, 77:9912-9921.
50. Harrich D, McMillan N, Munoz L, Apolloni A, Meredith L: Will diverse Tat interactions lead to novel antiretroviral drug targets? Curr Drug Targets 2006, 7:1595-1606.
51. Peruzzi F: The multiple functions of HIV-1 Tat: proliferation versus apoptosis. Front Biosci 2006, 11:708-717.
52. Bertrand SJ, Aksenova MV, Mactutus CF, Booze RM: HIV-1 Tat protein variants: critical role for the cysteine region in synaptodendritic injury. Exp Neurol 2013, 248:228-235.
53. Rosen CA, Sodroski JG, Goh WC, Dayton AI, Lippke J, Haseltine WA: Posttranscriptional regulation accounts for the trans-activation of the human T-lymphotropic virus type III. Nature 1986, 319:555-559.
54. Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, Dauguet C, Axler-Blin C, Vezinet-Brun F, Rouzioux C, Rozenbaum W, Montagnier L: Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983, 220:868-871.
55. Aksenova MV, Aksenov MY, Adams SM, Mactutus CF, Booze RM: Neuronal survival and resistance to HIV-1 Tat toxicity in the primary culture of rat fetal neurons. Exp Neurol 2009, 215:253-263.
56. Samikkannu T, Rao KV, Gandhi N, Saxena SK, Nair MP: Human immunodeficiency virus type 1 clade B and C Tat differentially induce indoleamine 2, 3-dioxygenase and serotonin in immature dendritic cells: Implications for neuroAIDS. J Neurovirol 2010, 16:255-263.
57. Mishra M, Vetrivel S, Siddappa NB, Ranga U, Seth P: Clade-specific differences in neurotoxicity of human immunodeficiency virus-1 B and C Tat of human neurons: significance of dicysteine C30C31 motif. Ann Neurol 2008, 63:366-376.
58. Rao VR, Sas AR, Eugenin EA, Siddappa NB, Bimonte-Nelson H, Berman JW, Ranga U, Tyor WR, Prasad VR: HIV-1 clade-specific differences in the induction of neuropathogenesis. J Neurosci 2008, 28:10010-10016.
59. Li W, Huang Y, Reid R, Steiner J, Malpica-Llanos T, Darden TA, Shankar SK, Mahadevan A, Satishchandra P, Nath A: NMDA receptor activation by HIV-Tat protein is clade dependent. J Neurosci 2008, 28:12190-12198.
60. Gandhi N, Saiyed Z, Thangavel S, Rodriguez J, Rao KV, Nair MP: Differential effects of HIV type 1 clade B and clade C Tat protein on expression of proinflammatory and antiinflammatory cytokines by primary monocytes. AIDS Res Hum Retroviruses 2009, 25:691-699.
61. Wong JK, Campbell GR, Spector SA: Differential induction of interleukin-10 in monocytes by HIV-1 clade B and clade C Tat proteins. J Biol Chem 2010, 285:18319-18325.
62. Kim BO, Liu Y, Ruan Y, Xu ZC, Schantz L, He JJ: Neuropathologies in transgenic mice expressing human immunodeficiency virus type 1 Tat protein under the regulation of the astrocyte-specific glial fibrillary acidic protein promoter and doxycycline. Am J Pathol 2003, 162:1693-1707.
63. Carey AN, Sypek EI, Singh HD, Kaufman MJ, McLaughlin JP: Expression of HIV-Tat protein is associated with learning and memory deficits in the mouse. Behav Brain Res 2012, 229:48-56.
64. Perez A, Probert AW, Wang KK, Sharmeen L: Evaluation of HIV-1 Tat induced neurotoxicity in rat cortical cell culture. J Neurovirol 2001, 7:1-10.
65. Carter PJ: Introduction to current and future protein therapeutics: a protein engineering perspective. Exp Cell Res 2011, 317:1261-1269.
66. Czajkowsky DM, Hu J, Shao Z, Pleass RJ: Fc-fusion proteins: new developments and future perspectives. EMBO Mol Med 2012, 4:1015-1028.
67. Suzuki T, Ishii-Watabe A, Tada M, Kobayashi T, Kanayasu-Toyoda T, Kawanishi T, Yamaguchi T: Importance of neonatal FcR in regulating the serum halflife of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. J Immunol 2010, 184:1968-1976.
68. Lee TY, Tjin Tham Sjin RM, Movahedi S, Ahmed B, Pravda EA, Lo KM, Gillies SD, Folkman J, Javaherian K: Linking antibody Fc domain to endostatin significantly improves endostatin half-life and efficacy. Clin Cancer Res 2008, 14:1487-1493.
69. Jorgensen ML, Friis NA, Just J, Madsen P, Petersen SV, Kristensen P: Expression of single-chain variable fragments fused with the Fc-region of rabbit IgG in Leishmania tarentolae. Microb Cell Fact 2014, 13:9.
70. Carter J, Zhang J, Dang TL, Hasegawa H, Cheng JD, Gianan I, O'Neill JW, Wolfson M, Siu S, Qu S, Meininger D, Kim H, Delaney J, Mehlin C: Fusion partners can increase the expression of recombinant interleukins via transient transfection in 2936E cells. Protein Sci 2010, 19:357-362.
71. Klein JS, Gnanapragasam PN, Galimidi RP, Foglesong CP, West AP Jr, Bjorkman PJ: Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10. Proc Natl Acad Sci U S A 2009, 106:7385-7390.
72. Morgan JR, LeDoux JM, Snow RG, Tompkins RG, Yarmush ML: Retrovirus infection: effect of time and target cell number. J Virol 1995, 69:6994-7000.
73. Englund U, Ericson C, Rosenblad C, Mandel RJ, Trono D, Wictorin K, Lundberg C: The use of a recombinant lentiviral vector for ex vivo gene transfer into the rat CNS. Neuroreport 2000, 11:3973-3977.
74. Gavegnano C, Kennedy EM, Kim B, Schinazi RF: The impact of macrophage nucleotide pools on HIV-1 reverse transcription, viral replication, and the development of novel antiviral agents. Mol Biol Int 2012, 2012:625983.
75. Diamond TL, Roshal M, Jamburuthugoda VK, Reynolds HM, Merriam AR, Lee KY, Balakrishnan M, Bambara RA, Planelles V, Dewhurst S, Kim B: Macrophage tropism of HIV-1 depends on efficient cellular dNTP utilization by reverse transcriptase. J Biol Chem 2004, 279:51545-51553.
76. Jamburuthugoda VK, Chugh P, Kim B: Modification of human immunodeficiency virus type 1 reverse transcriptase to target cells with elevated cellular dNTP concentrations. J Biol Chem 2006, 281:13388-13395.
77. Deglon N, Tseng JL, Bensadoun JC, Zurn AD, Arsenijevic Y, Pereira De Almeida L, Zufferey R, Trono D, Aebischer P: Self-inactivating lentiviral vectors with enhanced transgene expression as potential gene transfer system in Parkinson's disease. Hum Gene Ther 2000, 11:179-190.
78. Lu-Nguyen NB, Broadstock M, Schliesser MG, Bartholomae C, von Kalle C, Schmidt M, Yáñez-Muñoz RJ: Transgenic expression of human glial cell line-derived neurotrophic factor (hGDNF) from integration-deficient lentiviral vectors is neuroprotective in a rodent model of Parkinson's disease. Hum Gene Ther 2014, 25(7):631-641.
79. Ericson C, Georgievska B, Lundberg C: Ex vivo gene delivery of GDNF using primary astrocytes transduced with a lentiviral vector provides neuroprotection in a rat model of Parkinson's disease. Eur J Neurosci 2005, 22:2755-2764.
80. Dou H, Grotepas CB, McMillan JM, Destache CJ, Chaubal M, Werling J, Kipp J, Rabinow B, Gendelman HE: Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of neuroAIDS. J Immunol 2009, 183:661-669.
81. Ji KA, Yang MS, Jeong HK, Min KJ, Kang SH, Jou I, Joe EH: Resident microglia die and infiltrated neutrophils and monocytes become major inflammatory cells in lipopolysaccharide-injected brain. Glia 2007, 55:1577-1588.
82. Lebson L, Nash K, Kamath S, Herber D, Carty N, Lee DC, Li Q, Szekeres K, Jinwal U, Koren J, Dickey CA, Gottschall PE, Morgan D, Gordon MN: Trafficking CD11b-positive blood cells deliver therapeutic genes to the brain of amyloid-depositing transgenic mice. J Neurosci 2010, 30:9651-9658.
83. Wang H, Sun J, Goldstein H: Human immunodeficiency virus type 1 infection increases the in vivo capacity of peripheral monocytes to cross the blood-brain barrier into the brain and the in vivo sensitivity of the blood-brain barrier to disruption by lipopolysaccharide. J Virol 2008, 82:7591-7600.
84. Miron VE, Franklin RJ: Macrophages and CNS remyelination. J Neurochem 2014, 130(2):165-171.
85. Prinz M, Tay TL, Wolf Y, Jung S: Microglia: unique and common features with other tissue macrophages. Acta Neuropathol 2014, 128(3):319-331.
86. McMillan J, Batrakova E, Gendelman HE: Cell delivery of therapeutic nanoparticles. Prog Mol Biol Transl Sci 2011, 104:563-601.
87. Biju K, Zhou Q, Li G, Imam SZ, Roberts JL, Morgan WW, Clark RA, Li S: Macrophage-mediated GDNF delivery protects against dopaminergic neurodegeneration: a therapeutic strategy for Parkinson's disease. Mol Ther 2010, 18:1536-1544.
88. Ensoli B, Cafaro A: Control of viral replication and disease onset in cynomolgus monkeys by HIV-1 TAT vaccine. J Biol Regul Homeost Agents 2000, 14:22-26.
89. Re MC, Gibellini D, Furlini G, Vignoli M, Vitone F, Bon I, La Placa M: Relationships between the presence of anti-Tat antibody, DNA and RNA viral load. New Microbiol 2001, 24:207-215.
90. Richardson MW, Mirchandani J, Duong J, Grimaldo S, Kocieda V, Hendel H, Khalili K, Zagury JF, Rappaport J: Antibodies to Tat and Vpr in the GRIV cohort: differential association with maintenance of long-term nonprogression status in HIV-1 infection. Biomed Pharmacother 2003, 57:4-14.
91. Palfi S, Gurruchaga JM, Ralph GS, Lepetit H, Lavisse S, Buttery PC, Watts C, Miskin J, Kelleher M, Deeley S, Iwamuro H, Lefaucheur JP, Thiriez C, Fenelon G, Lucas C, Brugières P, Gabriel I, Abhay K, Drouot X, Tani N, Kas A, Ghaleh B, Le Corvoisier P, Dolphin P, Breen DP, Mason S, Guzman NV, Mazarakis ND, Radcliffe PA, Harrop R, et al: Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial. Lancet 2014, 383(9923):1138-1146.
92. Sierra-Filardi E, Nieto C, Dominguez-Soto A, Barroso R, Sanchez-Mateos P, Puig-Kroger A, Lopez-Bravo M, Joven J, Ardavin C, Rodriguez-Fernandez JL, Sánchez-Torres C, Mellado M, Corbí AL: CCL2 shapes macrophage polarization by GM-CSF and M-CSF: identification of CCL2/CCR2-dependent gene expression profile. J Immunol 2014, 192(8):3858-3867.
93. Jaguin M, Houlbert N, Fardel O, Lecureur V: Polarization profiles of human M-CSF-generated macrophages and comparison of M1-markers in classically activated macrophages from GM-CSF and M-CSF origin. Cell Immunol 2013, 281:51-61.
94. Biswas SK, Mantovani A: Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 2010, 11:889-896.
95. Cassol E, Cassetta L, Alfano M, Poli G: Macrophage polarization and HIV-1 infection. J Leukoc Biol 2010, 87:599-608.
96. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M: The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004, 25:677-686.
97. Grant RS, Naif H, Thuruthyil SJ, Nasr N, Littlejohn T, Takikawa O, Kapoor V: Induction of indolamine 2, 3-dioxygenase in primary human macrophages by human immunodeficiency virus type 1 is strain dependent. J Virol 2000, 74:4110-4115.
98. Afkhami-Goli A, Liu SH, Zhu Y, Antony JM, Arab H, Power C: Dual lentivirus infection potentiates neuroinflammation and neurodegeneration: viral copassage enhances neurovirulence. J Neurovirol 2009, 15:139-152.
99. Boasso A, Vaccari M, Hryniewicz A, Fuchs D, Nacsa J, Cecchinato V, Andersson J, Franchini G, Shearer GM, Chougnet C: Regulatory T-cell markers, indoleamine 2, 3-dioxygenase, and virus levels in spleen and gut during progressive simian immunodeficiency virus infection. J Virol 2007, 81:11593-11603.
100. Maneglier B, Malleret B, Guillemin GJ, Spreux-Varoquaux O, Devillier P, Rogez-Kreuz C, Porcheray F, Therond P, Dormont D, Clayette P: Modulation of indoleamine-2, 3-dioxygenase expression and activity by HIV-1 in human macrophages. Fundam Clin Pharmacol 2009, 23:573-581.
101. Fu X, Lawson MA, Kelley KW, Dantzer R: HIV-1 Tat activates indoleamine 2, 3 dioxygenase in murine organotypic hippocampal slice cultures in a p38 mitogen-activated protein kinase-dependent manner. J Neuroinflammation 2011, 8:88.
102. Samikkannu T, Saiyed ZM, Rao KV, Babu DK, Rodriguez JW, Papuashvili MN, Nair MP: Differential regulation of indoleamine-2, 3-dioxygenase (IDO) by HIV type 1 clade B and C Tat protein. AIDS Res Hum Retroviruses 2009, 25:329-335.
103. Potula R, Poluektova L, Knipe B, Chrastil J, Heilman D, Dou H, Takikawa O, Munn DH, Gendelman HE, Persidsky Y: Inhibition of indoleamine 2, 3-dioxygenase (IDO) enhances elimination of virus-infected macrophages in an animal model of HIV-1 encephalitis. Blood 2005, 106:2382-2390.
104. Sei S, Saito K, Stewart SK, Crowley JS, Brouwers P, Kleiner DE, Katz DA, Pizzo PA, Heyes MP: Increased human immunodeficiency virus (HIV) type 1 DNA content and quinolinic acid concentration in brain tissues from patients with HIV encephalopathy. J Infect Dis 1995, 172:638-647.
105. Sardar AM, Reynolds GP: Frontal cortex indoleamine-2, 3-dioxygenase activity is increased in HIV-1-associated dementia. Neurosci Lett 1995, 187:9-12.
106. Hryniewicz A, Boasso A, Edghill-Smith Y, Vaccari M, Fuchs D, Venzon D, Nacsa J, Betts MR, Tsai WP, Heraud JM, Beer B, Blanset D, Chougnet C, Lowy I, Shearer GM, Franchini G: CTLA-4 blockade decreases TGF-beta, IDO, and viral RNA expression in tissues of SIVmac251-infected macaques. Blood 2006, 108:3834-3842.
107. Suh HS, Zhao ML, Rivieccio M, Choi S, Connolly E, Zhao Y, Takikawa O, Brosnan CF, Lee SC: Astrocyte indoleamine 2, 3-dioxygenase is induced by the TLR3 ligand poly(I:C): mechanism of induction and role in antiviral response. J Virol 2007, 81:9838-9850.
108. Cassetta L, Kajaste-Rudnitski A, Coradin T, Saba E, Della Chiara G, Barbagallo M, Graziano F, Alfano M, Cassol E, Vicenzi E, Poli G: M1 polarization of human monocyte-derived macrophages restricts pre and postintegration steps of HIV-1 replication. AIDS 2013, 27:1847-1856.